# A Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Investigate the Efficacy, Safety and Duration of Effect of a Single Administration of Various Doses of Cetrorelix SR in Subjects With Histologically Confirmed Endometriosis

> **NCT00244452** · PHASE2 · COMPLETED · sponsor: **Solvay Pharmaceuticals**

## Conditions studied

- Endometriosis

## Interventions

- **DRUG:** Cetrorelix

## Key facts

- **NCT ID:** NCT00244452
- **Lead sponsor:** Solvay Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2006-09
- **Final completion:** 2006-09
- **Target enrollment:** — (—)
- **Last updated:** 2008-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00244452

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00244452, "A Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Investigate the Efficacy, Safety and Duration of Effect of a Single Administration of Various Doses of Cetrorelix SR in Subjects With Histologically Confirmed Endometriosis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00244452. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*